Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David S Lamb

Showing results (1-10 of 44) with videos related to

Pageof 5
Sort By:
The New Zealand Medical Journal|February 16, 2005
Prostate cancer screening--finding the middle road forwardDavid S Lamb, Brett Delahunt
The New Zealand Medical Journal|January 13, 2012
PSA testing--who should decide when it is performed?David S Lamb, Brett Delahunt, John N Nacey
Pathology|December 17, 2009
Gleason grading: consensus and controversyBrett Delahunt, John R Srigley, David S Lamb
The New Zealand Medical Journal|November 11, 2011
Revised status of PSA testing in the early detection and treatment of prostate cancerDavid S Lamb, Brett Delahunt, John N Nacey
The New Zealand Medical Journal|August 18, 2009
Survival benefit confirmed for prostate cancers diagnosed by PSA testingDavid S Lamb, Brett Delahunt, James Denham, et al.
Journal of Medical Radiation Sciences|June 29, 2016
Intensity-modulated radiotherapy in the treatment of locoregionally advanced head and neck cancer: implementation and outcomes in a New Zealand community hospitalChristopher N Rumley, Nikolay Nedev, Katrina Sharples, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 25, 2011
A methodology for the analysis of PSA response signaturesMartin A Ebert, David S Lamb, David J Joseph, et al.
Anticancer Research|February 6, 2009
Prostate cancer--are ethnic minorities disadvantaged?David S Lamb, Olivia Bupha-Intr, Peter Bethwaite, et al.
Brachytherapy|November 7, 2020
Relapse patterns after low-dose-rate prostate brachytherapyDavid S Lamb, Lynne Greig, Trevor FitzJohn, et al.
Pathology|December 5, 2013
Clinical significance of cancer in radical prostatectomy specimens: analysis from a contemporary series of 2900 menHemamali Samaratunga, Brett Delahunt, John Yaxley, et al.
Pageof 5

Showing results (1-10 of 44) with videos related to

Sort By:
Pageof 5
The New Zealand Medical Journal|February 16, 2005
Prostate cancer screening--finding the middle road forwardDavid S Lamb, Brett Delahunt
The New Zealand Medical Journal|January 13, 2012
PSA testing--who should decide when it is performed?David S Lamb, Brett Delahunt, John N Nacey
Pathology|December 17, 2009
Gleason grading: consensus and controversyBrett Delahunt, John R Srigley, David S Lamb
The New Zealand Medical Journal|November 11, 2011
Revised status of PSA testing in the early detection and treatment of prostate cancerDavid S Lamb, Brett Delahunt, John N Nacey
The New Zealand Medical Journal|August 18, 2009
Survival benefit confirmed for prostate cancers diagnosed by PSA testingDavid S Lamb, Brett Delahunt, James Denham, et al.
Journal of Medical Radiation Sciences|June 29, 2016
Intensity-modulated radiotherapy in the treatment of locoregionally advanced head and neck cancer: implementation and outcomes in a New Zealand community hospitalChristopher N Rumley, Nikolay Nedev, Katrina Sharples, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|January 25, 2011
A methodology for the analysis of PSA response signaturesMartin A Ebert, David S Lamb, David J Joseph, et al.
Anticancer Research|February 6, 2009
Prostate cancer--are ethnic minorities disadvantaged?David S Lamb, Olivia Bupha-Intr, Peter Bethwaite, et al.
Brachytherapy|November 7, 2020
Relapse patterns after low-dose-rate prostate brachytherapyDavid S Lamb, Lynne Greig, Trevor FitzJohn, et al.
Pathology|December 5, 2013
Clinical significance of cancer in radical prostatectomy specimens: analysis from a contemporary series of 2900 menHemamali Samaratunga, Brett Delahunt, John Yaxley, et al.
Pageof 5